An Open-label, Single Agent, Phase I/II Trial Investigating the Safety and Efficacy of RVU120 (SEL120) in Patients With Relapse / Refractory Metastatic or Advanced Solid Tumors
Latest Information Update: 23 Jan 2024
At a glance
- Drugs RVU 120 (Primary)
- Indications Adenoid cystic carcinoma; Advanced breast cancer; Colorectal cancer; Gastric cancer; Male breast cancer; Malignant thymoma; Oesophageal cancer; Pancreatic cancer; Solid tumours; Testicular cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms AMNYS-51
- Sponsors Ryvu Therapeutics
- 16 Jan 2024 Planned End Date changed from 1 Nov 2023 to 1 May 2025.
- 16 Jan 2024 Planned primary completion date changed from 1 Nov 2023 to 1 May 2025.
- 24 Oct 2023 According to Results presented in a Ryvu Therapeutics media release, Dose escalation is currently ongoing with PK modeling indicating high target engagement.